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Abstract
Cholangiocarcinoma (CCA) is a hepatobiliary malignancy exhibiting high incidence in countries 
with endemic liver-fluke infection. We analysed 489 CCAs from 10 countries, combining whole-
genome (71 cases), targeted/exome, copy-number, gene expression, and DNA methylation 
information. Integrative clustering defined four CCA clusters – Fluke-Positive CCAs (Clusters 
1/2) are enriched in ERBB2 amplifications and TP53 mutations, conversely Fluke-Negative CCAs 
(Clusters 3/4) exhibit high copy-number alterations and PD-1/PD-L2 expression, or epigenetic 
mutations (IDH1/2, BAP1) and FGFR/PRKA-related gene rearrangements. Whole-genome 
analysis highlighted FGFR2 3′UTR deletion as a mechanism of FGFR2 upregulation. Integration 
of non-coding promoter mutations with protein-DNA binding profiles demonstrates pervasive 
modulation of H3K27me3-associated sites in CCA. Clusters 1 and 4 exhibit distinct DNA 
hypermethylation patterns targeting either CpG islands or shores – mutation signature and 
subclonality analysis suggests that these reflect different mutational pathways. Our results 
exemplify how genetics, epigenetics and environmental carcinogens can interplay across different 
geographies to generate distinct molecular subtypes of cancer.
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INTRODUCTION
Cholangiocarcinoma (CCA) is the second most common hepatobiliary malignancy, 
accounting for 10–20% of primary liver cancers (1). The highest rates of CCA are in South 
East Asia (Northeast Thailand, Cambodia, and Laos), where >8,000 cases are diagnosed 
annually due to infection by liver flukes such as Opisthorchis viverrini and Clonorchis 
sinensis (2). CCA is considered relatively rare in Western countries (<6 per 100,000 
population) where risk factors such as primary sclerosing cholangitis, hepatolithiasis and 
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choledochal cysts predominate (3). However, the incidence of intrahepatic CCA in the USA 
appears to be increasing (1).
Current 5-year survival rates for CCA after surgery and chemotherapy remain poor [<20%, 
(4)], and clinical trials evaluating targeted therapies in unselected CCA populations have 
shown minimal benefits (5). Existing CCA classification systems are primarily based on 
either anatomical location (intrahepatic, perihilar, and distal) or pathological features 
(cirrhosis, viral hepatitis, and primary sclerosing cholangitis), which do not provide insights 
into mechanisms of CCA tumorigenesis, nor potential targets for therapy. While previous 
exome-sequencing studies by our group and others have revealed a complex CCA 
mutational landscape (6–8), no study to date has compared fluke-positive and fluke-negative 
CCAs at the whole-genome level, nor fully explored the extent and contribution of structural 
variants and non-coding regulatory mutations to CCA pathogenesis. Little is also known 
about epigenetic differences between fluke-positive and fluke-negative CCAs.
Here, on behalf of the International Cancer Genome Consortium, we report an integrated 
genomic, epigenomic and transcriptomic analysis of CCA involving nearly 500 CCAs from 
ten countries. Comprehensive integrative clustering revealed four CCA clusters likely driven 
by distinct etiologies, with separate genetic, epigenetic, and clinical features. Our analysis 
uncovered new driver genes (RASA1, STK11, MAP2K4, SF3B1) and structural variants 
(FGFR2 3′ UTR deletion). Within the non-coding genome, we observed a significant 
enrichment of promoter mutations in genes regulated by epigenetic modulation, uncovered 
through a novel analysis framework incorporating experimentally-derived protein-DNA 
binding affinities and pathway information. Strikingly, we found that two of the CCA 
clusters displayed distinct patterns of DNA hypermethylation enriched at different genomic 
regions (CpG islands vs shores), demonstrating for the first time the existence of distinct 
DNA methylation subgroups of CCA. We propose that tumors from these two subtypes may 
have arisen through distinct mechanisms of carcinogenesis, driven by either extrinsic 
carcinogenic agents or intrinsic genetic insults.
RESULTS
CCA Whole-Genome Sequencing and Integrative Clustering
Whole-genome sequencing (WGS) was performed on 71 CCA tumors and non-malignant 
matched tissues, including both fluke-associated (Fluke-Pos, 22 O. viverrini and 1 C. 
cinensis samples) and non-fluke associated cases (Fluke-Neg, 48 samples). Of these, 27 
samples have been previously analysed at the exome level (6–8) (Supplementary Tables 1A–
B). Sequencing was performed to an average depth of 64.2× (median 65.1×; Supplementary 
Table 1C). We called somatic mutations (single-nucleotide variants (sSNVs) and short 
insertion-deletions (indels)) using both Genome Analysis Toolkit and MuTect 
(Supplementary Methods). Orthogonal validation resequencing on 97 randomly selected 
sSNVs and 85 indels using either Ion Torrent or Sanger technologies determined accuracy 
rates to be 99% for sSNVs and 87% for indels. In total, we detected 1,309,932 somatic 
mutations across the 71 tumors, with 4,541 nonsilent sSNVs and 1,251 nonsilent indels in 
protein-coding genes. On average, each CCA had 82 nonsilent somatic mutations per tumor 
(median 47), consisting of 64 nonsilent somatic sSNVs (median 41) and 18 indels (median 
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6). These mutation counts are comparable to those previously observed in genomes from 
pancreatic cancer (9) (74 sSNVs and 5 indels per tumor), liver cancer with biliary phenotype 
(10) (79 sSNVs and 24 indels per tumor) and hepatocellular carcinoma (11) (70 sSNVs and 
6 indels per tumor). Three CCAs exhibited exceptionally high mutation levels (average 5.91 
sSNVs/Mb and 24.17 indels/Mb, vs. 1.39 and 3.72 for other CCAs) – these tumors exhibited 
mutational signatures of microsatellite instability (MSI) and two of these cases exhibited 
PolE mutations. Excluding these three hypermutated cases, Fluke-Pos CCAs exhibited 
significantly more somatic mutations compared to Fluke-Neg CCAs (median 4,700 vs. 3,143 
per tumor, p < 0.05, Wilcoxon rank-sum test).
Previous studies by our group have suggested that genomic alterations in CCA may differ 
according to causative etiology (6–8). However, definitive exploration of these differences 
has been missing, due to limitations in sample sizes and genes analysed, reliance on a single 
genomic platform (exome), and lack of whole-genome information. To address these 
limitations, we assembled a cohort of 489 CCAs (Supplementary Tables 1A–B) including 
133 Fluke-Pos (132 O. viverrini and 1 C. cinensis samples) and 356 Fluke-Neg cases. 
Samples were analysed using four different genomic platforms based on sample availability. 
Besides WGS (71 cases), these included exome sequencing of 200 cases (previously 
published (8)), high-depth targeted sequencing of 188 cases, SNP array copy-number 
profiling of 175 cases, array-based DNA methylation profiling of 138 cases, and array-based 
expression profiling of 118 cases. To confirm the applicability of merging different 
datatypes, we used statistical models to confirm that our mutation calls were not biased by 
differences in sequencing platforms, and directly confirmed mutation concordance by 
analysing those samples sequenced on overlapping platforms (Supplementary Methods). 
Using iClusterPlus, we performed integrative clustering combining data from somatic 
mutations, somatic copy-number alterations (sCNAs), mRNA expression and DNA 
methylation on 94 CCAs where all four data types were available. Randomized subsampling 
clustering confirmed the robustness of these integrative clusters (Supplementary Fig. 1A). To 
support the reliability of our conclusions, reanalysis using an expanded set of integrative 
clustered samples (121 samples), including samples with one or more missing platforms 
while retaining a cluster prediction accuracy of 90%, yielded similar results and associations 
(Supplementary Fig. 1B, Supplementary Methods). We also found that while the most 
discriminatory clustering was achieved by using all available genomic information, 
clustering by individual modalities recapitulated some of the integrative clusters, for sCNA, 
expression, and methylation data (Supplementary Fig. 1C, see later section on DNA 
methylation). Importantly, integrative clustering performed on samples stratified by 
anatomical location reproduced the original clusters within each anatomical site (≥ 88% 
concordance; Supplementary Fig. 1D), demonstrating that the molecular clusters are not 
simply recapitulating anatomical variation.
Integrative clustering revealed 4 distinct clusters characterized by different clinical features 
and genomic alterations (Fig. 1A). Cluster 1 comprised mostly Fluke-Pos tumors, with 
hypermethylation of promoter CpG islands (aberrantly methylated above normal level, 
Supplementary Methods), enrichment of ARID1A and BRCA1/2 mutations (p < 0.01 and p 
< 0.05 respectively, Fisher’s exact test), high levels of nonsynonymous mutations (p < 0.001, 
Wilcoxon rank-sum test, Supplementary Fig. 2A), and high levels of mutations in gene 
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promoters with histone 3 lysine 27 trimethylation (H3K27me3) predicted to alter 
transcription factor binding (see later section on somatic promoter mutations). Cluster 2 was 
characterized by a mix of Fluke-Pos and Fluke-Neg tumors, with upregulated CTNNB1, 
WNT5B and AKT1 expression (p < 0.05, Wilcoxon rank-sum test, Supplementary Fig. 2B) 
and downregulation of genes involving EIF translation initiation factors (Supplementary 
Table 2A). Most notably, Clusters 1 and 2 were also significantly enriched in TP53 
mutations and ERBB2 amplifications (p < 0.001 and p < 0.01 respectively, Fisher’s exact 
test) and elevated ERBB2 gene expression (p < 0.05, Wilcoxon rank-sum test, Fig. 1A and 
Supplementary Fig. 2C).
In contrast to Clusters 1 and 2, Clusters 3 and 4 comprised mostly Fluke-Neg tumors. 
Cluster 3 displayed the highest level of sCNAs, including enrichment of amplifications at 
chromosome arms 2p and 2q (q < 0.05, Fisher’s exact test; Supplementary Table 2B). 
Analysis of immune populations by ESTIMATE revealed that both Clusters 2 and 3 
displayed immune cell infiltration (Supplementary Fig. 2D), but only Cluster 3 exhibited 
specific upregulation of immune checkpoint genes (PD-1, PD-L2 and BTLA) (Fig. 1B and 
Supplementary Fig. 2E) and pathways related to antigen cross-presentation, CD28 co-
stimulation, and T cell signal transduction (Supplementary Table 2A). Cluster 4 was 
characterized by BAP1, IDH1/2 mutations, FGFR alterations (all p < 0.01, Fisher’s exact 
test), and upregulated FGFR family and PI3K pathway signatures (Fig. 1A and 
Supplementary Table 2A). Similar to Cluster 1, Cluster 4 tumors also exhibited DNA 
hypermethylation – however, rather than hypermethylation at CpG islands, Cluster 4 
hypermethylation was at CpG promoter shores (see later section on DNA methylation).
We sought to relate the CCA clusters to anatomical and clinical features. Clusters 1 and 2 
were enriched in extrahepatic (consisting of perihilar and distal) tumors while Clusters 3 and 
4 were composed almost entirely of intrahepatic tumors (p < 0.001, Fisher’s exact test). This 
was observed in both fluke-negative and fluke-positive tumors, and persisted after adjusting 
for fluke status (p < 0.001, multivariate regression; also confirmed in expanded clusters). 
Other CCA risk factors, such as Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), and 
primary sclerosing cholangitis (PSC), were present in our cohort at frequencies of 10.4%, 
2.9%, and 1.0% respectively. Both HBV and PSC were associated with intrahepatic CCA (p 
< 0.05, Fisher’s exact test) (12).
We further investigated the prevalence of driver genes according to anatomical location 
(among 459 samples with sequencing and anatomical location information). BAP1 and 
KRAS were more frequently mutated in intrahepatic cases (q < 0.1, Fisher’s exact test). This 
was observed in both fluke-negative and fluke-positive tumors, and persisted even after 
adjusting for fluke status (q < 0.1, multivariate regression). No additional genes were 
identified as differentially mutated when the extrahepatic CCAs were analysed as perihilar 
and distal CCAs.
Clinically, patients in Clusters 3 and 4 had significantly better overall survival relative to the 
other 2 clusters (p < 0.001, log-rank test; Fig. 1C). As fluke infection was also associated 
with poorer survival (p < 0.001, log-rank test; Supplementary Fig. 2F), we performed 
multivariate analysis and confirmed that this cluster-associated survival difference persisted 
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even after accounting for fluke association, anatomical location, and clinical staging (p < 
0.05, Cox proportional hazards model; Supplementary Table 2C). To validate this finding, 
we assembled a separate validation cohort comprising newly-classified samples from the 
expanded integrative clustering and a recently-published set of CCA samples (13) 
(Supplementary Methods). A survival analysis on this independent validation cohort 
reaffirmed the same survival trends, on both univariate (p < 0.05, log-rank test; 
Supplementary Fig. 2F) and multivariate analysis (p < 0.05, Cox proportional hazards 
model; Supplementary Table 2C). This result demonstrates that molecular clusters can 
provide additional prognostic information in a manner independent of fluke status and 
anatomical location. Fig. 1D summarizes the salient features of each CCA cluster.
New CCA Driver Genes and Structural Rearrangements
Driver gene mutation analysis across 459 CCAs (130 Fluke-Pos and 329 Fluke-Neg cases) 
revealed 32 significantly mutated genes (SMGs, q < 0.1 by both MutSigCV and IntOGen; 
Supplementary Tables 3A–D and Fig. 2A). Our analysis revealed four potentially new CCA 
driver genes not highlighted in previous CCA publications (6–8,13–17) – RASA1, STK11, 
MAP2K4, and SF3B1. Of these, RASA1, STK11, and MAP2K4 are related to RAS/MAPK 
signalling (Fig. 2B–C and Supplementary Table 3B). RASA1, encoding a p120 Ras GTPase-
activating protein, was predicted to be inactivated in 4.1% of cases (10 frame shift, 4 
nonsense; Fig. 2D). These inactivating mutations, along with observed focal RASA1 copy-
number losses, were associated with decreased RASA1 expression (Fig. 2E). In CCA cell 
lines, shRNA-mediated knockdown of RASA1 resulted in significantly enhanced migration 
and invasion, supporting a tumor-suppressor role for RASA1 in CCA (Fig. 2F). STK11, a 
serine/threonine protein kinase, was mutated in 5% of cases, with most STK11 mutations 
also predicted to be inactivating (7 nonsense, 9 frame shift; Fig. 2G). SF3B1, an RNA 
splicing factor, was mutated in 4.6% of cases, at mutation hotspots (23% at codon 625 and 
14% at codon 700) previously observed in uveal melanoma and breast cancer (18,19) (Fig. 
2H). This latter finding may implicate a role for RNA splicing dysregulation in CCA 
tumorigenesis. MAP2K4 is a member of the mitogen-activated protein kinase, and has been 
shown to activate p38 mitogen-activated protein kinase and c-Jun N-terminal kinase. We 
observed MAP2K4 focal homozygous deletions in two Fluke-Pos cases (Supplementary Fig. 
3A–C), and MAP2K4 mutations in another 10 cases (2.2%). Half of these were predicted to 
be inactivating (frameshift, nonsense, splice site mutations), consistent with a tumor 
suppressor role for MAP2K4 in CCA.
ERBB2 was amplified in 3.9 – 8.5% of CCAs (Supplementary Table 3E). ERBB2 
amplifications were more frequent in Fluke-Pos cases (10.4% in Fluke-Pos vs 2.7% in 
Fluke-Neg CCA, p < 0.01, Fisher’s exact test) with elevated ERBB2 gene expression in 
Fluke-Pos compared to Fluke-Neg tumors in these cases (Supplementary Fig. 2C, 
Supplementary Table 3E for validation samples). On average, ERBB2 amplified samples 
exhibited 14 ERBB2 copies (copy numbers determined by ASCAT (SNParray) or Quandico 
(sequencing data)), and GSEA analysis confirmed upregulation of ERBB2-related gene sets 
among ERBB2-amplified samples (q < 0.2; Supplementary Table 3F). We independently 
validated the presence of ERBB2 amplification in selected cases by flouresence in-situ 
hybridization (FISH; Supplementary Fig. 3D). Other pathways upregulated in ERBB2-
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amplified samples included biological oxidation, metabolism cytochrome P450, peroxisome 
proliferator-activated receptors signaling and checkpoint signaling (q < 0.2). In addition to 
ERBB2 amplifications, we also detected activating ERBB2 mutations (S310F/Y, G292R, 
T862A, D769H, L869R, V842I, G660D) in 9 cases (2%). Notably, previous studies in cell 
lines have shown that high ERBB2-expressing CCAs may be more sensitive to ERBB2-
inhibitor treatment compared to low ERBB2-expressing cases, suggesting that tumors with 
high ERBB2 expression may be candidates for anti-ERBB2/HER2 therapy (20). 
Amplification of other selected oncogenes included MYC (n = 12), MDM2 (n = 9), EGFR 
(n = 11), and CCND1 (n = 7), while deletions included CDKN2A (n = 17), UTY (n = 17), 
and KDM5D (n = 16) (Supplementary Table 3G).
Availability of WGS data also allowed us to investigate the role of SVs in CCA. Using 
CREST, we identified ~93 somatic SVs per tumor (median 69, range 0 to 395), with a 91% 
(61/67) true positive rate by PCR. Most of the SVs were intra-chromosomal (65%), and 
associated with cancer-related genes (ARID1A, CDKN2A/B), retrotransposon-associated 
genes (TTC28), and fragile sites (1q21.3) (Supplementary Table 4). SV burden varied 
significantly across the 4 CCA clusters (p < 0.05, Kruskal-Wallis test), with Fluke-Neg 
tumors in Cluster 4 associated with low burden (p < 0.05, 1-sided Wilcoxon rank-sum test). 
TP53, FBXW7 and SMAD4 were significantly associated with increased SV burden (q < 
0.1, Wilcoxon rank-sum test; Supplementary Fig. 4A).
FGFR2 fusion genes, previously reported in CCA (21), are thought to deregulate FGFR2 
signalling through the hijacking of 3′ fusion partners with dimerization motifs (21,22). 
However, whether rearrangements affecting other FGFR members (besides FGFR2) exist in 
CCA, or if other categories of FGFR2 rearrangements (besides in-frame gene fusions) can 
contribute to CCA development, remain unclear. Analysis of the WGS data, followed by 
subsequent validation at the gene transcript level, revealed 5 in-frame gene fusions with 
intact tyrosine kinase domains – four involving FGFR2 (FGFR2-STK26, FGFR2-TBC1D1, 
FGFR2-WAC, and FGFR2-BICC1) (Fig. 3A) and one involving FGFR3 (FGFR3-TACC3) 
(Fig. 3B). To our knowledge, this is the first report of FGFR3 fusions in CCA. FGFR3-
TACC3 fusions have been previously reported in bladder cancer, glioblastoma, and lung 
cancer (23,24) and were shown to be oncogenic.
Besides FGFR in-frame fusions, we also identified recurrent truncating events translocating 
FGFR2, without its 3′ UTR, to intergenic regions (Fig. 3C). FGFR2-truncated CCAs 
exhibited high expression levels compared to FGFR2 transcripts with intact 3′UTRs (p < 
0.01, Wilcoxon rank-sum test). In vitro, luciferase reporter experiments confirmed 
diminished expression in constructs containing FGFR2 3′UTRs compared to control 
reporters (Fig. 3D). FGFR2 3′UTR loss may thus represent a new and additional mechanism 
for enhancing FGFR2 expression in CCA, similar to mechanisms reported for PD-L1 (25).
FGFR2 rearrangements were observed exclusively in Cluster 4 (p < 0.001, Fisher’s exact 
test) (Fig. 1A). In CCAs lacking FGFR rearrangements, we further identified other genomic 
alterations involving FGFR2 including indels (n=3), SNVs (n=10), and copy-gains (n=1) – 
several of these alterations have been previously shown to be activating (26,27). Collectively, 
CCAs with altered FGFR2 genes (point mutations, indels, copy-gain and rearrangements) 
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were significantly enriched in Cluster 4 (p < 0.01, Fisher’s exact test) and also expressed 
significantly higher FGFR2 levels than FGFR2-wildtype tumors (Fig. 1A, Fig. 2B and Fig. 
3E).
In addition to FGFR fusions, WGS analysis also identified rearrangements affecting the 
catalytic subunit B of cAMP-dependent protein kinase A (PRKACB), including ATP1B1-
PRKACB and LINC00261-PRKACB (Fig. 3F). Both PRKACB rearrangements retained the 
PRKACB pseudokinase domain, and thus may increase PKA activity and activate 
downstream MAPK signalling (8).
Long interspersed nuclear element-1 (LINE-1 or L1) repeats are autonomous 
retrotransposons collectively occupying ~17% of the human genome. Recent studies have 
shown that certain L1 elements are active in cancer, displaying somatic retrotransposition 
and potentially contributing to genomic instability and tumorigenesis (28–30). In the CCA 
WGS samples, we observed frequent somatic L1 retrotranspositions, particularly originating 
from an L1 element in intron 1 of the TTC28 gene (52 events in 20/71 tumors, 28.2%, 
Supplementary Fig. 4B). PCR testing validated 98% (46/47) of these retrotransposition 
events (Supplementary Table 4). CCAs with L1 retrotransposition were associated with 
Fluke-Pos tumors (p < 0.01, Fisher’s exact test) and increased SV burden (p < 0.05, 
Wilcoxon rank-sum test), suggesting a relationship between genomic instability and L1 
endonuclease activity. Further analysis revealed that these intragenic insertions were not 
overtly associated with cancer-related genes, such as tumor suppressors.
CCA Somatic Promoter Mutations
Somatic mutations in noncoding regulatory regions have been proposed to play crucial roles 
in carcinogenesis (31). However, systematic approaches for identifying such mutations are 
lacking and their effects in CCA remain poorly understood. To date, only TERT promoter 
mutations have been observed in CCA (8), and in our WGS cohort, only two CCAs (2.8%) 
harboured TERT-promoter mutations (chr5:1295228). Besides TERT, no other recurrent 
non-coding promoter-region mutations were observed in the WGS cohort.
Even when integrating mutations over regulatory regions or gene promoters, the low 
recurrence rate of most noncoding mutations may lead to a lack of statistical power to 
identify potential drivers in the promoters of individual genes. We hypothesized that the 
effects of noncoding promoter mutations might instead be detectable at the gene-set level. To 
test this hypothesis, we developed a novel method, FIREFLY (FInding Regulatory mutations 
in gEne sets with FunctionaL dYsregulation, Fig. 4A), which identifies gene sets 
dysregulated by somatic promoter mutations that alter transcription factor (TF) binding. 
Compared to approaches used in previous cancer genome studies (32,33), FIREFLY differs 
in three important respects. First, it uses experimentally determined high-throughput TF-
DNA binding data for 486 TFs representing a broad range of TF families (34,35), as 
opposed to position weight matrices (PWMs) (36), to predict mutation-associated changes in 
TF binding affinity. Second, FIREFLY condenses the large numbers of highly non-recurrent 
noncoding mutations into biologically-meaningful gene sets, shortlisting those sets with an 
overrepresentation of mutations, as assessed by multiple statistical tests. Third, it 
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orthogonally validates the transcriptional consequences of the binding-change predictions 
using expression data from primary tumors.
To identify sets of genes that had dysregulated transcription in the aggregate due to promoter 
mutations, we applied FIREFLY to 70 WGS samples (1 hypermutated sample was 
excluded), representing 6,639 somatically mutated gene promoters. Based on binding-
change predictions, FIREFLY identified 138 sets of genes that were enriched for binding-
change mutations in promoters (q < 0.1, Fisher’s exact test with Benjamini-Hochberg false 
discovery rate). FIREFLY’s second statistical test then compared the number of binding-
change mutations in these sets to an expected null distribution determined from synthetically 
mutated data, created using the tumor-specific mutation rates for each type of mutation in its 
trinucleotide context. Nineteen sets passed the second test (q < 0.1). Finally, FIREFLY 
orthogonally assessed the transcriptional impact of the binding-change predictions, by 
testing whether tumors with increasing numbers of binding-change mutations for a given 
gene set also exhibit greater transcriptional dysregulation in that set (q < 0.1, by Gene Set 
Analysis (37)). Four of the 19 sets were validated by this test (Fig. 4B; see Fig. 4C and 
Supplementary Fig. 5A for example non-significant gene sets). This was significantly 
greater than expected for a null distribution based on randomly selected gene sets of similar 
sizes (p < 0.01; Supplementary Fig. 5B). We note that FIREFLY results do not imply that 
every somatic promoter mutation in the 4 gene sets affects gene expression. Instead, the 
results indicate that the identified sets have excesses of promoter mutations that likely affect 
gene expression. We also note that FIREFLY does not use predicted gain or loss of binding 
to infer directionality of change in expression levels. This is because, in general, TFs can act 
as either activators or repressors depending on the regulatory context. Consequently, one 
cannot in general predict whether a gain or loss of a binding site will result in up or down-
regulation.
To validate a fundamental assumption in the FIREFLY pipeline, i.e. that mutations predicted 
to alter TF binding also affect transcription, we selected three mutations and tested them in 
luciferase reporter assays. We confirmed altered regulatory activity for two of the three 
mutations, providing direct evidence that mutations predicted to change TF binding can in 
fact alter gene expression (Supplementary Fig. 5C).
FIREFLY identified 4 gene sets that were likely dysregulated by altered TF-DNA binding. 
Interestingly, two of these (MIKKELSEN_MCV6_HCP_WITH_H3K27ME3 and 
MIKKELSEN_MEF_ICP_WITH_H3K27ME3) are subsets of PRC2 target genes that have 
promoters with histone modification H3K27me3 in certain contexts (Fig. 4B). Mutations in 
all 4 enriched gene sets occurred across all four of the CCA clusters. It was noteworthy, 
however, that Cluster 1 was enriched for mutations in 3 of the 4 gene sets, including two 
associated with H3K27me3 (Supplementary Fig. 5D). This, together with the observed 
hypermethylation of Polycomb Repressive Complex 2 (PRC2) target genes in Cluster 1 (see 
later section on DNA methylation), provides additional evidence of the importance of 
alterations in PRC2 regulation in Cluster 1.
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Distinct CCA Epigenomic Subtypes
As shown in Fig. 1, iCluster analysis revealed two distinct hypermethylated CCA subgroups 
(Clusters 1 and 4). To validate these differences across a larger CCA series, we performed 
unsupervised DNA-methylation clustering on an expanded panel of 138 CCAs. Clustering 
based solely on DNA methylation recapitulated two hypermethylated clusters highly 
concordant with Clusters 1 and 4 (96.3% and 86.1% concordance respectively; Fig. 5A), and 
a third group of low-methylation tumors representing a mix of Clusters 2 and 3. Cluster 1, 
enriched in Fluke-Pos CCAs, was dominated by hypermethylation in promoter CpG islands, 
while Cluster 4, enriched in Fluke-Neg CCAs, was dominated by hypermethylation in 
promoter CpG island shores (Fig. 5B). Different sets of gene promoters were targeted for 
hypermethylation in Clusters 1 and 4. However, Gene Set Enrichment Analysis (GSEA) 
revealed that both affected common pathways, including PRC2 targets. We observed 
significant inverse correlations between transcript levels and promoter methylation in both 
Cluster 1 and 4 (q < 0.05; Supplementary Fig. 6A), consistent with these epigenetic 
alterations exerting transcriptional impact.
DNA hypermethylation in the two hypermethylated clusters may be driven by distinct 
epigenetic mechanisms. In Cluster 1, we observed downregulation of the DNA 
demethylation enzyme TET1 and upregulation of the histone methyltransferase EZH2 
(Supplementary Fig. 6B), suggesting a possible role for these genes in establishing the 
hypermethylation phenotype (38). In contrast, Cluster 4 CCAs were significantly enriched in 
IDH1/2 mutations, which are known to be associated with CCA hypermethylation (7,13,39) 
(31.6% in Cluster 4 versus 1.0% in other clusters, q < 0.001, multivariate regression; Fig. 
5A). Among Cluster 4 CCAs lacking IDH1/2 mutations (68.4%), BAP1 mutations were 
enriched (q < 0.001 and 0.05 respectively for inactivating point mutations and regional 
deletions; Fig. 5A). BAP1 mutated cases were also associated with increased CpG 
hypermethylation relative to BAP1 wildtype cases (Supplementary Fig. 6C). Notably, BAP1 
mutations have been associated with DNA hypermethylation in CCA and renal cell 
carcinoma (13,40).
To explore mutation patterns between these two clusters, we identified ten established 
mutation signatures in the WGS cohort. These included COSMIC Signatures 1, 5, 8, 16, and 
17, and signatures associated with activated APOBECs (Signatures 2 and 13), mismatch-
repair deficiency (MMR, Signatures 6 and 20), and aristolochic acid exposure (Signature 22, 
Supplementary Fig. 6D). Signature 5 burdens were correlated with patient age (Spearman 
correlation 0.25, p < 0.05) as previously reported for other cancer types (41). Fluke-Pos 
CCAs were enriched for activated APOBEC mutation burden (p < 0.001, multivariate 
regression). Signatures of MMR and Signatures 8, 16 and 17 have not been previously 
reported in CCA.
We observed elevated levels of Signature 1 (CpG>TpG mutations) in Cluster 1, even after 
adjusting for patient age (p < 0.001, multivariate regression; Fig. 5C). Importantly, this 
elevation is Signature 1-specific, as it was not observed for Signature 5. We note that CpG 
dinucleotides are known mutation hotspots, due to spontaneous deamination of 5-
methylcytosine (5mC) to thymine (CpG>TpG mutation) (42). To investigate if 
hypermethylated CpGs in Cluster 1 might provide susceptible genomic substrates for 
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deamination and subsequent Signature 1 mutations, we integrated the locations of the 
CpG>TpG mutations with regions of hypermethylation. In Cluster 1, CpG>TpG mutations 
were indeed located preferentially near hypermethylated regions (p < 0.001, Fisher’s exact 
test; Fig. 5D and Supplementary Fig. 6E), whereas in Cluster 4 these mutations showed no 
such regional preferences. These results support a significantly increased level of DNA 
hypermethylation-related deamination events in Cluster 1 compared to Cluster 4.
We further investigated if the differences in genome-wide mutation patterns between clusters 
are accompanied by distinct clonal structures harbouring these mutations. Distribution 
analysis of variant allele frequencies (VAFs) for point mutations (in copy-neutral regions and 
adjusted for tumor purity) revealed a wide spread of VAFs in Cluster 1 compared to Cluster 
4 (Fig. 5E), indicating the presence of heterogeneous subclones in Cluster 1 tumors, but not 
in Cluster 4 tumors. Together, these distinct patterns of hypermethylation-related 
deamination and tumor heterogeneity suggest disparate somatic-evolution processes during 
tumorigenesis in these clusters (see Discussion).
DISCUSSION
Surgery is the only proven treatment modality for CCA (43), and all formal evaluations of 
targeted therapies to date, performed in unselected CCA cohorts, have proved unsuccessful 
(44). In this study, we analysed a cohort of nearly 500 CCAs from distinct geographical 
regions, including 94 CCAs covered by four genomic platforms. Integrative clustering of 
mutation, copy number, gene expression, and epigenetic data revealed four subtypes of 
CCA, each exhibiting distinct molecular and clinicopathologic features. Four lines of 
evidence highlight that clustering based on molecular profiles provides additional 
information beyond anatomical site. Firstly, anatomical site does not drive molecular 
subtypes, as evidenced by the reproducibility of the molecular subtypes within each 
anatomical site separately (Supplementary Fig. 1D). Secondly, tumors in different 
anatomical sites may exhibit similarities at the molecular level, while tumors located in the 
same anatomical site can display profound differences in their molecular profiles. This is 
exemplified by Clusters 1 and 2 comprising mixtures of intrahepatic and extrahepatic 
tumors, while intrahepatic tumors are split among all 4 clusters. Thirdly, from a disease 
prognosis standpoint, CCAs in different anatomical sites do not differ in their survival 
trends, whereas the molecular clusters show significant differences in survival, in both the 
original and an independent validation cohort (Fig. 1C and Supplementary Fig. 2F). Finally, 
we note that current medical oncology guidelines do not discriminate CCA treatments based 
on their anatomical site (1) as classifications based on anatomy do not provide information 
regarding potential therapeutic opportunities. In contrast, the molecular profiles highlight 
several potential cluster-specific therapies (see next paragraph). Taken collectively, our 
results indicate that molecular CCA subtypes based on integrative molecular clustering are 
likely to offer enhanced information regarding CCA biology and clinical behaviour, beyond 
that provided by anatomical location alone.
Examination of signature genomic alterations in each subtype highlights potential 
therapeutic opportunities, although we emphasize that such findings require further clinical 
validation. For example, it is possible that CCAs in Clusters 1 and 2 with ERBB2 
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amplification may be appropriate for therapies targeting ERBB2/HER2 signaling (45). The 
elevated expression of immune related genes and pathways in Cluster 3 CCAs suggests a 
therapeutic opportunity for immunotherapy, however this conclusion should be treated with 
caution due to the small sample size of this cluster. The specific mechanisms driving the 
elevated expression of immune-related genes in Cluster 3 remain unclear, however increased 
levels of immunogenicity and upregulation of MHC protein and antigen processing 
complexes have been independently observed in aneuploid tumors (46,47), consistent with 
the elevated level of chromosomal aberrations in Cluster 3. Cluster 4 CCAs, which are 
associated with IDH1/2 mutations and FGFR2 and PRKA-related gene rearrangements, 
might also be tested with recently described IDH inhibitors (ClinicalTrials.gov identifier: 
NCT02073994) or FGFR-targeting agents. Notably, our study suggests that loss of 
FGFR2-3′ UTRs may represent an alternative mechanism of FGFR2 activation, beyond 
FGFR2 in frame gene fusions and activating mutations. This, along with our additional 
observation of FGFR3 rearrangements, expands the proportion of potential FGFR-targetable 
cases in CCA (48).
Previous cancer studies have discovered recurrent regulatory mutations in individual 
promoters such as TERT (33,49). In complement to these studies, we developed in this work 
an alternative analysis framework (FIREFLY), which uses protein binding microarray 
(PBM)-based analysis to examine the effects of non-coding promoter mutations on gene-
expression pathways in cancer. FIREFLY’s use of PBM data with a k-mer-based approach 
provides advantages for estimating the effects of mutations on TF binding affinitites 
compared to traditional PWM models. For example, PWMs implicitly assume that each base 
pair contributes independently to binding affinity, however this is not always true. Moreover, 
PWMs do not capture the multiple modes of binding associated with many TFs, and PWM 
scores are not easily comparable between TFs. FIREFLY addresses these shortcomings by 
using experimentally determined PBM data, which provides actual binding affinities of 
every possible 8-mer. Using FIREFLY, we identified several pathways with strong statistical 
evidence for recurrent systematic dysregulation in CCA. Interestingly, two of these pathways 
reflected epigenetically-modulated cellular differentiation processes, which have been 
shown to be dysregulated in cancer in general by other means such as DNA 
hypermethylation or histone modification.
Of the four clusters, two clusters (Cluster 1 and 4) are most clearly distinguished by their 
highly distinctive patterns of genome-wide DNA hypermethylation, targeting either 
promoter CpG islands or promoter CpG shores. To our knowledge, such epigenetically 
distinct tumor subtypes have not been previously reported in the literature, particularly for 
tumors from the same tissue-type. Further analysis demonstrated that Cluster 1 CCAs are 
Fluke-Pos with elevated mutation rates, Mutation Signature 1 enrichment, and increased 
point-mutation subclonality, while Cluster 4 CCAs are Fluke-Neg and by comparison 
relatively clonal. We propose that these differences are consistent with a model where early 
in tumorigenesis, Cluster 1 CCAs are likely driven by external carcinogenic agents and early 
epigenetic deregulation (“epimutations”), while Cluster 4 CCAs are likely driven by pioneer 
genetic events such as IDH1/2 or BAP1 mutations, with epigenetic aberrations arising as a 
downstream consequence (Fig. 6). In this model, fluke infection, by inducing chronic 
inflammation, metabolic disruption of host bile homeostasis (50), or secretion of fluke 
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growth factors and excretory vesicles for modulating host-pathogen interactions (51), 
induces genome-wide epigenetic deregulation. Cytosine residues experiencing aberrant 
methylation are then at higher risk of spontaneous deamination and mutation, consistent 
with the enrichment of Signature 1 mutations in this subtype. CpG island hypermethylation 
in this subtype may also silence tumor suppressor genes, further enhancing cancer 
development. Moreover, because the processes of carcinogen-induced methylation, 
deamination, and mutation are inherently stochastic from cell to cell, such events would 
inevitably lead to increased levels of intra-tumor heterogeneity. In contrast, in Cluster 4 
CCAs which are Fluke-Neg, somatic mutations in critical chromatin modifier genes (e.g. 
IDH1/2 and BAP1) may occur as a primary event preceding epigenetic deregulation, driving 
both rapid clonal outgrowth and directly inducing DNA hypermethylation. Specifically, 
IDH1/2 mutations have been shown to increase 2-hydroxyglutarate oncometabolite 
production, leading to DNA hypermethylation.
We acknowledge that other models may also explain the striking molecular differences 
between Cluster 1 and 4. These include differential vulnerabilities in distinct cells-of-origin, 
as the biliary system is known to contain multipotent stem/progenitor cells. Liver fluke 
infection primarily affects large intra and extra- hepatic bile ducts, giving rise to intra and/or 
extra-hepatic CCA. Conversely, parenchymal liver diseases exclusively affect canals of 
Hering and bile ductules, and are primarily associated with intrahepatic CCA (52).
A recent study from the USA TCGA consortium reported a multi-omic analysis of a smaller 
and more-homogenous CCA series (38 samples, exclusively fluke-negative, mostly 
intrahepatic and North American) (13). Comparison of this study to our own data revealed 
an obvious difference – specifically our inclusion of Fluke-Pos samples allowed the 
discovery of another major CCA subtype (Cluster 1) with distinct clinical and molecular 
features. Besides Cluster 1, the other study’s “IDH” (IDH mutants) and “METH3” (BAP1 
mutants and FGFR rearrangements) groups are likely matches to our Cluster 4 
(characterized by IDH and BAP1 mutants, and FGFR rearrangements); while their “ECC” 
group (extrahepatic) matched Cluster 2 (containing fluke-negative extrahepatic tumors). On 
the other hand, the TCGA “METH2” group (CCND1 amplifications) and our Cluster 3 were 
not obviously matched. Taken collectively, these results suggest that most of the TCGA 
study’s clusters are largely concordant with our own, and neither classification strictly 
precludes the other.
We acknowledge that limitations of sample resources (DNA, RNA and paraffin-embedded 
tissues) were a major constraint in this study. We were unable to generate data using all 
platforms on all samples, which reduced the sample size in the integrative clustering 
analysis. To overcome this constraint, we sequenced an extended and separate sample 
cohort, to validate findings emerging from the integrative clustering. Centre-specific 
differences in pre-sample processing steps, including collection site, biopsy site, and sample 
processing protocols, may also result in sequencing biases. We attempted to control for these 
variations by reviewing the histology of all cases using standardized AJCC 7th criteria to 
confirm and harmonize the histology and anatomical subtype of samples. We also attempted 
to reduce biopsy bias and normal contamination originating from the biopsy sites by 
estimating tumor cell content through histopathological review or SNP arrays. Lastly, our 
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study merged data from different DNA sequencing platforms (WGS, WES, and targeted 
sequencing), thus limiting our analysis across the entire cohort to genomic regions common 
to these platforms. However, we overcome biases from different data processing centers and 
merging different data types by using one analysis pipeline, ensuring uniform analysis on 
each data type, and confirming good concordance between samples sequenced on multiple 
platforms (Supplementary Methods).
In summary, integrative analysis of a large CCA cohort has revealed a novel molecular 
taxonomy, with discovery of new potential CCA driver genes and gene rearrangements. This 
taxonomy may be clinically relevant, however more functional data is required to test the 
validity of the genomic data. Analysis of non-coding promoter mutations, made possible by 
whole-genome analysis, revealed that they play a significant role in CCA targeting genes 
involved in PRC2 biology, and we identified two highly distinct CCA subtypes 
demonstrating distinct DNA hypermethylation patterns. We conclude by noting that these 
last two findings may carry conceptual relevance beyond biliary tract cancers. Specifically, 
while elevated DNA methylation levels have been observed in numerous cancers, these cases 
to date been largely consigned to a general CIMP (CpG Island Methylator Phenotype) class 
– our data suggests that a more detailed examination of these cases may reveal potential for 
epigenetic heterogeneity. Finally, as exemplified by the TERT promoter, previous analyses 
of non-coding promoter mutations have largely focused on identifying individual regions of 
recurrent genomic aberration. Our FIREFLY analysis suggests that such cases are likely 
rare, and that similar to protein coding genes, mutations in non-coding regulatory regions 
may target genes in specific pathways rather than individually. Extending this concept to 
promoter mutation catalogues of other cancer types will certainly test the general 
applicability of this proposition.
METHODS
Sample collection
Primary tumor and matched normal samples (non-neoplastic liver or whole blood) were 
obtained from the SingHealth Tissue Repository (Singapore), Fundeni Clinical Institute 
(Romania), Khon Kaen University (Thailand), ARC-Net Biobank (Italy), Centre de 
Ressources Biologiques Paris-Sud (France), Department of Pathology, Yonsei University 
College of Medicine (South Korea), Hospital do Cancer de Barretos (Brazil), Linkou Chang 
Gung Memorial Hospital (Taiwan) and Department of Pancreatobiliary Surgery, The First 
Affiliated Hospital, Sun Yat-Sen University (China) with signed informed consent. WGS 
data from 10 Japanese cases were also included (National Cancer Center, Japan). The study 
was approved by the SingHealth Centralised Institutional Review Board (2006/449/B), 
Ethics Committee of the Clinical Institute of Digestive Diseases and Liver Transplantation, 
Fundeni (215/18.01.2010), Khon Kaen University (HE471214), Centre de Ressources 
Biologiques Paris-Sud, National Cancer Center, Japan (G20-03), Severance Hospital, Yonsei 
University Health System (4-2014-0829), Hospital do Cancer de Barretos (716/2013), 
Linkou Chang Gung Memorial Hospital (100-2030B), The First Affiliated Hospital of Sun 
Yat-Sen University (2014/C_006) and ARC-Net Biobank at Verona University Hospital (n. 
prog. 1959). Clinico-pathological information for subjects including age, sex, histology, 
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tumor subtype, stage and overall survival were reviewed retrospectively. Cases were staged 
according to the American Joint Committee on Cancer (AJCC) Staging System 7th Edition. 
All patients had not received prior treatment. In total, 489 tumors with associated 
clinicopathologic data were obtained (133 Fluke-Pos: 132 O. viverrini, 1 C. sinensis; 39 
HBV/HCV-positive; 5 PSC-positive). These were assayed on at least one profiling platform, 
which included: (1) WGS (71 CCAs); (2) targeted sequencing surveying 404 genes (188 
CCAs); (3) published exome sequencing ((8); 200 CCAs); (4) HumanOmniExpress 
BeadChip arrays (SNP arrays; 175 CCAs); (5) DNA methylation 450k BeadChip arrays 
(138 CCAs) and (6) HumanHT-12 Expression BeadChip arrays (Gene expression arrays; 
118 CCAs) (Supplementary Table 1 and Supplementary Table 5). A detailed list of clinical 
data is included in Supplementary Table 1A.
Cell lines
H69 non-malignant immortalized cholangiocyte cells were obtained in 2011, from D. 
Jefferson (New England Medical Center, Tufts University) and cultured as previously 
described (53). HEK293T cells were obtained from ATCC (CRL-3216) in 2015 and cultured 
with Dulbecco’s Modified Eagle’s Medium, 10% Fetal Bovine Serum, 2mM L-glutamine 
and 1% Penicillin/Streptomycin. EGI-1 was purchased from DSMZ (ACC 385) and 
maintained in DMEM supplemented with 10% FBS (Sigma-Aldrich). HUCCT1 
(JCRB0425) cells were purchased from the Health Sciences Research Resources Back 
(HSRRB) in 2009 and maintained in RPMI1640 medium with 10% FBS. M213 (JCRB1557) 
cells were obtained from the Liver Fluke and Cholangiocarcinoma Research Center in 2015 
and cultured with Ham’s F12 media (Gibco). Cells were cultured at 37 °C in a 5% CO2 
humidified chamber. All cell lines were authenticated by short-tandem repeat (STR) 
profiling and found to be negative for mycoplasma as assessed by the MycoSensor qPCR 
Assay Kit (Agilent Technologies).
Sample preparation and sequencing
Genomic DNA was extracted using the QIamp DNA mini kit (Qiagen). DNA yield and 
quality were determined using Picogreen (Invitrogen) and further visually inspected by 
agarose gel electrophoresis. RNA was extracted using an RNeasy mini kit (Qiagen), 
quantified by measuring Abs260 with a UV spectrophotometer, and quality assessed with 
the Agilent 2100 Bioanalyzer (Agilent Technologies). Sequencing libraries were prepared 
from DNA extracted from tumor and normal samples using the SureSelect XT2 Target 
Enrichment System for the Illumina Multiplexed Sequencing platform (Illumina) according 
to the manufacturer’s instructions. Whole-genome sequencing was performed using Illumina 
Hiseq X10, Illumina Hiseq2500 and Illumina Hiseq2000 instruments. To survey the 
frequency and distribution of somatic mutations in the validation cohort (188 CCAs), 
targeted sequencing of 404 genes was performed after capture with a custom SureSelect 
capture reagent designed using the SureDesign tool (Agilent Technologies). Target-enriched 
libraries were sequenced on the Illumina HiSeq 4000 sequencing platform. Coverage of 
coding regions based on the amplicon design was 99.6% (Supplementary Table 5).
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Reporter assays
For 3′ UTR Reporter Assays, control reporter plasmids (LUC) were generated by cloning 
the SV40 promoter into the pGL4.10 promoterless luciferase reporter vector (Promega). The 
LUC-FGFR2_3′UTR test plasmid was engineered by inserting the 1,666 bp 3′UTR region 
of FGFR2 (starting from stop codon) into the immediate 3′ end of luciferase gene of the 
LUC plasmid. HEK293T or H69 cells were cotransfected with a Renilla-containing plasmid 
with either LUC or LUC-FGFR2_3′UTR. Transfected cells were incubated for 24 hours.
For promoter mutation reporter assays, Luciferase constructs were generated by ligating 
fragments of promoter regions (2 kb upstream and 500 bp downstream of the TSS) prepared 
from genomic PCR using gene-specific primers. Mutant constructs were generated using the 
QuikChange II XL site-directed mutagenesis kit (Agilent Technologies) according to the 
manufacturer’s instructions. H69 or EGI-1 cells were transfected and incubated for 48 hours, 
after which Dual-Luciferase Reporter Assays (Promega) were performed. Relative luciferase 
activity was calculated as the firefly luciferase activity normalized to Renilla (Promega) 
luciferase activity. Assays were conducted in triplicates and each experiment was repeated 3 
independent times.
RASA1 shRNA silencing and Functional Assays
Construction of hairpin-pLKO.1 vectors (carrying a puromycin antibiotic resistance gene) 
containing shRNAs targeting RASA1 coding sequences were performed as follows: 
shRNA#1 
(CCGGGCTGCAAGAACACTGATATTACTCGAGTAATATCAGTGTTCTTGCAGCTTTT
TG, TRCN0000356449, Sigma) and shRNA#2 (CCGGCCTGGCGATTATTCA 
CTTTATCTCGAGATAAAGTGAATAATCGCCAGGTTTTT, TRCN0000005998, Sigma). 
Lentivirus particles were produced in HEK-293T cells transfected with psPAX2, PMD2G 
(Addgene) and pLKO.1-shRNA-containing plasmids. M213 and HUCCT1 cells were 
infected with the lentivirus, and stable cells were established by puromycin selection 
(Sigma). Migration assays were performed in Transwells (Corning Inc., 8.0-μm pore size). 
For migration, 2.5 × 104 cells of RASA1 stably-silenced M213 and HUCCT1 cells in serum-
free medium were added to 24-well insert plates. Media containing 10% FBS were added to 
the lower wells and incubated for 5 h. For cell invasion assays, the filters were pre-coated 
with Matrigel. 2.5 × 104 cells of RASA1 stably-silenced M213 and HUCCT1 cells in serum-
free medium were added into 24-well insert plates. Media containing 10% FBS was added to 
the lower well of the chambers and incubated for 5 h. After incubation, the cells on the 
upper surface of the filter were completely removed and migrated cells were trypsinized and 
counted.
Somatic mutation detection
We aligned sequence data to the human reference genome (hs37d5) using BWA-MEM 
v0.7.9a (54). We removed PCR duplicates using SAMTools (55) and performed indel 
realignments using Genome Analysis Toolkit v1.0 (GATK) (56). We used realigned data as 
input to both GATK Unified Genotyper and MuTect to call sSNVs (somatic single 
nucleotide variants). We used GATK IndelGenotyperV2 to identify indels. We applied filters 
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and manual inspection to retain only high confidence sSNVs and indels. Further details are 
provided in the Supplementary Methods.
Analysis of somatic promoter mutations with FIREFLY
FIREFLY (FInding Regulatory mutations in gEne sets with FunctionaL dYsregulation) is a 
method for identifying gene sets dysregulated by somatic promoter mutations through 
modulation of TF binding. We extracted somatic promoter mutations by selecting non-
coding sSNVs within +/− 2kb of TSSs of GENCODE genes. We identified those mutations 
predicted to change TF-binding based on PBM data (details below). We then evaluated gene 
sets for enrichment in promoter binding-change mutations. For each gene set, we calculated 
the test statistic M = number of genes in the gene set with binding-change mutations, 
summed across all tumors. To identify gene sets enriched in binding-change mutations, we 
performed two statistical tests in sequence, where gene sets found significant in each test (q 
< 0.1) were then tested in the next: (1) Fisher’s exact test; (2) a synthetic mutations test. For 
gene sets passing these tests, we then performed gene expression tests using the “GSA” 
v1.03 R package (37) to assess their transcriptional dysregulation. Further details are 
provided in the Supplementary Methods.
We generated synthetic mutations in promoter regions of interest based on the genome-wide 
frequency of mutations at each trinucleotide observed for each tumor/normal pair. Synthetic 
mutations were generated separately for each tumor, based on the frequencies and mutation 
types observed in the actual tumor. Further details are provided in the Supplementary 
Methods.
Identifying TF binding-change mutations
To identify binding-change mutations, we used TF-DNA binding specificity PBM data from 
the cis-BP database (34). PBM experiments measure TF binding to all possible 8-mer 
sequences with a DNA binding enrichment score (E-score) (35). Typically, E-scores > 0.35 
correspond to specific TF-DNA binding (57). To call binding sites for a particular TF, we 
required that such sites contain at least two consecutive 8-mers with E-scores > 0.4. We also 
used PBM data to call ‘non-binding sites’ defined as genomic regions containing only 8-
mers with E-score < 0.3. For each somatic mutation and each TF with available PBM data, 
we analyzed the 15-bp genomic region centered at the mutation. If the region contains a TF 
binding site in the normal sample but not in the corresponding tumor sample, the mutation 
was called a ‘loss-of-binding’ mutation for that TF. If the region contains a TF binding site 
in the tumor sample but not in the normal sample, then the mutation was called ‘gain-of-
binding’ for that TF. We describe a mutation as ‘binding-change’ if it is either loss-of-
binding or gain-of-binding for any of the interrogated TFs. Further details are provided in 
the Supplementary Methods.
Driver gene analysis
We integrated (i) 71 WGS CCAs, (ii) 188 targeted-sequenced CCAs (Supplementary Table 
5), and (iii) 200 exome-sequenced CCA (8), and performed gene significance analyses using 
MutSigCV (58) and IntOGen (59). For input, we used the list of all coding sSNVs and 
indels found in the 404 targeted genes across 459 samples (including both silent and 
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nonsilent mutations). Both tools were run with default parameters and we retained genes 
found significant by both tools with q values <0.1. Further details are provided in the 
Supplementary Methods.
Detection and annotation of structural variations
BWA-MEM alignments from each tumor-normal pair were analyzed by CREST (Clipping 
REveals STructure) (60) and PTRfinder (61). For most tumours we required ≥ 3 uniquely 
mapped split-read alignments at each SV breakpoint; for the shallower Japanese WGS data 
we required only ≥ 5 such alignments over both SV breakpoints combined. We considered a 
tumor SV to be somatic if no SV in the normal sample occurred within one-half of a read 
length from the tumor SV. Further details are provided in the Supplementary Methods.
Identification of L1-retrotransposition insertions
We searched for sources of somatic L1 insertions by looking for highly recurrent SVs: ≥ 10 
SVs in a 1Mb region. We then selected the subset of these region that contained a mobile L1 
element in a database of retrotransposon insertion polymorphisms (dbRIP) (62). Only SVs 
with ≥ 2 reads with poly-A tails at the putative L1 insertion site were retained for further 
analysis.
Validation of structural variations
For genomic DNA, 100 ng of whole-genome amplified DNA of the tumor and normal 
matched cases were used as PCR templates. For cDNA, total cDNAs of tumor and normal 
matched control were synthesized using SuperScript III System according to manufacturer’s 
instructions (Invitrogen) and 40 ng of cDNA were used as PCR template. PCR was 
performed using fusion-specific primers with Platinum Taq DNA Polymerase system 
(Invitrogen). PCR products were cleaned up by the Exo/Sap enzyme system (Invitrogen) and 
bidirectionally sequenced using the BigDye Terminator v.3.1 kit (Applied Biosystems) and 
an ABI PRISM 3730 Genetic Analyzer (Applied Biosystems). Sequencing traces were 
aligned to reference sequences using Lasergene 10.1 (DNASTAR) and analysed by visual 
inspection.
Somatic L1 insertions were validated by PCRs using primers flanking predicted sites of 
insertion. PCRs were performed using AccuPrime™ Pfx DNA Polymerase (Invitrogen) with 
200 ng of WGA DNA.
Copy-number analysis
Raw SNP array data was processed using Illumina Genome Studio. We used ASCAT v2.0 
(63) to estimate allele-specific copy-number profiles. We determined regions of copy-
number alteration based on their relative copy-number using the “copynumber” R package 
(64). For tumor-normal pairs without SNP array data, we estimated copy-number profiles 
based on sequencing data using Control-FREEC (65), Quandico (66), and Sequenza (67). 
We used GISTIC v2.0.22 (68) to determine regions of significant focal copy-number 
alterations, using ASCAT/Sequenza’s inferred copy-number segments, and associated copy-
number values were defined as log2 of the segment’s relative copy-number. Full details are 
provided in the Supplementary Methods.
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Gene expression analysis
Gene expression microarray data was pre-processed using the “lumi” R package (69). Batch 
effects were removed using ComBat (70). We used GSEA v2.2.2 (71) with a classic 
weighting scheme to determine pathways upregulated or downregulated in each integrative 
CCA cluster relative to the others, employing canonical pathways in the MSigDB C2 
catalogue of annotated gene sets. Full details are provided in the Supplementary Methods.
Immune cell infiltration analysis
ESTIMATE (72) was used to determine the presence of infiltrating immune cells, using the 
ImmuneSignature geneset. A total of 126 genes were used to determine the immune score 
for each tumor.
DNA methylation analysis
DNA methylation profiles were obtained for 138 tumors and 4 normal samples. Data was 
preprocessed using the “minfi” (73) and “wateRmelon” (74) R packages. We selected 4,520 
probes with the highest standard deviations in β-values across the tumors, and mean β < 0.5 
in the normal samples, for clustering using the “RPMM” R package (75). In the 
hypermethylated methylation clusters (1 and 4), we considered a CpG site to be 
hypermethylated if the following conditions held: (1) β < 0.5 in normal samples; (2) M-
values were significantly different in the (i) hypermethylated cluster versus (ii) the combined 
normal samples and the low-methylation tumors—those not in methylation cluster 1 or 4 (q 
< 0.05, two-sided t-test); and (3) its mean β in the hypermethylated cluster minus the mean β 
across the normal samples and low-methylation tumors was > 0.2.
To explore associations between mutation signatures and hypermethylated CpGs, we 
considered only mutations located within 50 bp of CpG probes that had mean β < 0.5 in 
normal samples. In each tumor, the nearest CpG probe to a mutation was considered to be 
hypermethylated if it was: (1) hypermethylated in that tumor’s methylation cluster; (2) its 
individual β was > 0.5; and (3) its individual β minus the mean β across the normal samples 
and low-methylation tumors was > 0.2. Other analyses were similar to community-standard 
analyses. Further details are provided in the Supplementary Methods.
Integrative clustering
The “iClusterPlus” R package (76) was used to perform integrative unsupervised clustering 
of 94 CCAs based on 4 genomic data types: (i) somatic point mutations in 404 targeted 
genes (gene by sample matrix of binary values), (ii) sCNAs defined as copy-number 
segments identified by ASCAT v2.0, (iii) the most variable expression probes (coefficient of 
variation > 0.1), and (iv) the most variable methylation probes (top 1% standard deviation in 
β-value). We ran iClusterPlus.tune with different numbers of possible clusters (n=2 to 7), 
choosing the number of clusters at which the percentage of explained variation leveled off 
(n=4), and the clustering with the lowest Bayesian information criterion (BIC). Further 
details are provided in the Supplementary Methods.
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Survival analysis
The “survival” R package was used to perform survival analysis using Kaplan-Meier 
statistics, with p-values computed by log-rank tests. Multivariate survival analysis was 
performed using the Cox proportional hazards method. To validate our survival analysis 
results, we also analysed a separate validation cohort of 58 samples, by combining two 
sources: (i) 25 samples (with survival data) newly classified into CCA clusters under the 
expanded integrative clustering; and (ii) 33 recently-published CCA samples with survival 
data from Farshidfar et al. (2017) (13). Further details are provided in the Supplementary 
Methods.
Mutation signature analysis
Non-negative matrix factorization (NMF) was applied to the trinucleotide-context mutation 
spectra of CCAs to extract mutation signatures. Six stable and reproducible extracted 
mutational signatures were compared to the 30 signatures from the Catalogue of Somatic 
Mutations in Cancer (COSMIC) (http://cancer.sanger.ac.uk/cosmic/signatures) based on 
cosine similarities. We used supervised NMF to evaluate the contributions of the COSMIC 
signatures to mutations in CCA. Additional signatures were considered via visual inspection. 
We ignored signatures that contributed < 5% of the total mutations in a particular tumor, and 
removal of these signatures did not substantially increase reconstruction errors. The MSI 
status in the prevalence set was determined by the indel counts in simple repeat sequences. 
Further details are provided in the Supplementary Methods.
Additional information
Accession codes—The whole genome and targeted sequencing data done in this paper 
have been deposited at the European Genome-phenome Archive (EGA; http://
www.ebi.ac.uk/ega) under accession numbers EGAS00001001653 and at the International 
Cancer Genome Consortium Data Portal database (https://dcc.icgc.org/). The whole exome 
sequencing data (8) has been deposited at EGA under accession number EGA00001000950. 
Gene expression and Methylation data have been deposited at the Gene Expression Omnibus 
(GEO; www.ncbi.nlm.nih.gov/geo) with GEO accession numbers GSE89749 and 
GSE89803, respectively.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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STATEMENT OF SIGNIFICANCE
Integrated whole-genome and epigenomic analysis of cholangiocarcinoma (CCA) on an 
international scale identifies new CCA driver genes, non-coding promoter mutations, and 
structural variants. CCA molecular landscapes differ radically by etiology, underscoring 
how distinct cancer subtypes in the same organ may arise through different extrinsic and 
intrinsic carcinogenic processes.
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Figure 1. Integrative Clustering Defines Four Molecular Subtypes of CCA
(A) Heatmap showing four clusters identified by iClusterPlus based on clustering of 
mutation, copy-number, gene expression and methylation data. Top rows indicate clinical 
characteristics, risk factors, geographical region, and sequencing platform. Microsatellite 
instability (MSI) status was defined by indel counts (≥ 6 indels) in simple repeat sequences. 
Bottom rows indicate selected genetic alterations.
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(B) High expression of PD-1, PD-L2 and BTLA in Cluster 3 relative to other clusters. 
Brown dots indicate MSI cases. Pink dots indicate cases with DNA polymerase epsilon 
(POLE) proofreading deficiency.
(C) Survival analysis showing improved survival in Cluster 3 and 4 CCAs compared to other 
clusters. Multivariate analysis confirmed this difference even after accounting for fluke 
association, anatomical location, and clinical staging.
(D) Representative genetic, epigenetic and gene expression features of CCA clusters.
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Figure 2. Significantly Mutated Genes in CCAs
(A) Significantly mutated genes in Fluke-Pos and Fluke-Neg CCA. Genes in purple are 
mutated in both Fluke-Pos and Fluke-Neg CCAs. Novel significantly mutated genes are 
highlighted in red.
(B) Alterations in Kinase-Ras/Raf pathway components across Fluke-Pos and Fluke-Neg 
CCAs. CCAs with FGFR/PRKACB rearrangements are also highlighted (arrows).
(C) Matrix of genes (rows) and tumors (columns) showing occurrence of 32 somatic mutated 
genes. The bar chart at right shows frequencies of affected cases in Fluke-Pos and Fluke-
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Neg tumors. Asterisks indicate genes with significant differences between Fluke-Pos and 
Fluke-Neg CCAs. P-values were computed using the Fisher’s exact test.
(D) Distribution of somatic mutations in RASA1.
(E) RASA1 expression in tumors without RASA1 alterations (Wild-type) compared to 
tumors with RASA1 deletions and inactivating mutations (nonsense mutations or frame-shift 
indels).
(F) RASA1 shRNA silencing inhibits CCA migration and invasion in vitro. Expression 
levels (mRNA and protein) of RASA1 in M213 (left) and HUCCT1 (right) cells transduced 
with two independent shRNAs (RASA1 shRNA#1 and RASA1 shRNA#2) targeting 
different regions of RASA1 were assessed by qPCR and Western blotting (first and second 
panel, respectively). Migration and invasion of RASA1 knockdown cells were assessed by 
transwell assays. Mean ± SEM of three independent experiments were analyzed.
(G–H) Distribution of somatic mutations in STK11 (G) and SF3B1 (H). The red box 
indicates mutations in previously described SF3B1 hotspots.
Jusakul et al. Page 30
Cancer Discov. Author manuscript; available in PMC 2018 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 3. FGFR and PRKA Gene Rearrangements in CCA
(A) Identification of FGFR2-STK26, FGFR2-WAC and FGFR2-TBC1D1 and FGFR2-
BICC1 rearrangements in CCA. All fusions were validated by RT-PCR and sequence 
chromatograms are shown. FGFR2-STK26, FGFR2-WAC and FGFR2-TBC1D1 were 
validated in this study, while FGFR2-BICC1 was validated in (8).
(B) Identification of a FGFR3-TACC3 gene fusion. Transcript validation was performed 
confirming a 7 bp insertion (red dotted lines).
(C) Recurrent loss of 3′ UTRs in FGFR2 due to rearrangements with intergenic regions.
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(D) Relative luciferase activity between empty luciferase vector (LUC) and FGFR2-3′UTR 
in HEK293T and H69 immortalized cholangiocyte cell lines. Data is presented in Mean ± 
SD. Three individual experiments were performed.
(E) FGFR2 gene expression levels between FGFR2-wildtype CCAs and CCAs exhibiting 
different categories of FGFR2 alterations, as shown by the color chart.
(F) Identification of LINC00261-PRKACB and ATP1B1-PRKACB fusions. Both fusions 
were validated by RT-PCR and sequence chromatograms.
Jusakul et al. Page 32
Cancer Discov. Author manuscript; available in PMC 2018 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 4. FIREFLY Analysis of Pathways Systematically Dysregulated by Somatic Promoter 
Mutations that Alter Transcription Factor Binding
(A) Changes in transcription factor (TF)-DNA binding estimated from PBM (protein 
binding microarray) data for 486 mammalian TFs. Changes in binding specificity were 
computed using PBM-derived binding scores for 8-mer sequences overlapping each 
mutation. To determine whether a given gene set was preferentially enriched for binding-
change mutations, we computed the statistic M (the number of genes in the gene set with TF 
binding-change mutations in the promoter) summed over all tumors. FIREFLY assessed 
systematic enrichment of binding-change mutations with 2 statistical tests: (i) Fisher’s exact 
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test of whether M is greater than expected by chance given the number genes in the gene set 
and the total number of genes affected by binding-change mutations, (ii) a comparison of M 
in actual data to a null distribution of M over 1,000 sets of 70 in-silico mutated tumor 
sequences, based on patient-specific trinucleotide contexts of mutations for each tumor. 
FIREFLY then tests for putative transcriptional dysregulation associated with the binding-
change mutations by performing a Gene Set Analysis (GSA) to associate gene expression 
dysregulation with the number of binding-change mutations.
(B) Details of the four gene sets meeting FIREFLY’s criteria of q < 0.1 for all three 
statistical tests: MIKKELSEN_MCV6_HCP_WITH_H3K27ME3, 
MIKKELSEN_MEF_ICP_WITH_H3K27ME3, 
MARTORIATI_MDM4_TARGETS_NEUROEPITHELIUM_DN, and 
WONG_ENDOMETRIUM_CANCER_DN.
(C) Details of an example non-significant gene set.
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Figure 5. Epigenetic Clusters and Integration of Mutation Signatures in CCA
(A) Heatmap showing three DNA methylation clusters: two hypermethylated clusters 
(Cluster 1 and Cluster 4), and a low methylation cluster (mixed Clusters 2 and 3).
(B) Distinct methylation patterns in Cluster 1 versus Cluster 4. Top: typical organization of a 
gene promoter with CpG island and shores. Vertical ticks represent CpG sites. Bottom: 
Levels of promoter hypermethylation in CpG islands and shores in Cluster 1 and Cluster 4.
(C) Left: enrichment of mutation Signature 1 (CpG>TpG) in Cluster 1. Right: similar levels 
of mutation Signature 5 among methylation clusters. Circled tumors represent MSI tumors.
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(D) Proximity of somatic mutations to hypermethylated CpGs in Cluster 1 and 4. Left: 
CpG>TpG mutations are located preferentially near hypermethylated CpGs in Cluster 1, but 
not in Cluster 4. Right: Non C>T mutations are not located preferentially near 
hypermethylated CpGs in either Cluster 1 or 4.
(E) Histograms of corrected variant allele frequencies (VAF) of point mutations in Cluster 1 
and 4.
Jusakul et al. Page 36
Cancer Discov. Author manuscript; available in PMC 2018 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 6. Model for Distinct Pathways of CCA Tumorigenesis
A proposed model for CCA development in Clusters 1 and 4 being driven by distinct 
mechanisms. Cluster 1 may be initiated by extrinsic carcinogens (fluke-infection) causing 
genome-wide epigenetic derangement and subsequent spontaneous 5-methylcytosine 
deamination and CpG>TpG mutations. In contrast, in Cluster 4 CCAs, intrinsic genetic 
mutations in strong driver genes such as IDH1 reflect a primary initiating event and 
consequently drive DNA hypermethylation. See Discussion for details.
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